Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics
Pacific Biosciences of California, Inc. (PACB)
Today's Latest Price: $33.55 USD
Updated Jan 28 11:15am
Add PACB to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
PACB Stock Summary
- The price/operating cash flow metric for Pacific Biosciences Of California Inc is higher than 98.85% of stocks in our set with a positive cash flow.
- With a price/sales ratio of 70.24, Pacific Biosciences Of California Inc has a higher such ratio than 95.61% of stocks in our set.
- The volatility of Pacific Biosciences Of California Inc's share price is greater than that of 97.99% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Pacific Biosciences Of California Inc, a group of peers worth examining would be ACAD, PSNL, GWPH, JG, and CERS.
- Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to www.pacb.com.
PACB Stock Price Chart Interactive Chart >
PACB Price/Volume Stats
| Current price | $33.55 | 52-week high | $41.65 |
| Prev. close | $31.06 | 52-week low | $2.20 |
| Day low | $31.15 | Volume | 1,438,360 |
| Day high | $34.04 | Avg. volume | 5,551,078 |
| 50-day MA | $25.25 | Dividend yield | N/A |
| 200-day MA | $11.30 | Market Cap | 6.05B |
Pacific Biosciences of California, Inc. (PACB) Company Bio
Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.
PACB Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $33.55 | $0.02 | -100% |
We started the process of determining a valid price forecast for Pacific Biosciences Of California Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Pacific Biosciences Of California Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Pacific Biosciences Of California Inc ended up being:
- As a business, PACB is generating more cash flow than only 18.61% of positive cash flow stocks in the Healthcare.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 5.92% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Pacific Biosciences Of California Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -47.28. This coverage rate is greater than that of only 2.71% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -100% |
| 1% | -100% |
| 2% | -100% |
| 3% | -100% |
| 4% | -100% |
| 5% | -100% |
Want more companies with a valuation profile/forecast similar to that of Pacific Biosciences Of California Inc? See AGHC, ALC, AMRN, ATRS, and MOR.
Loading social stream, please wait...